Oncolytic Virus (OV) therapy is an immunotherapy that kills tumor cells based on the infection and replication of viruses within tumors. It still has significant advantages in terms of high replication efficiency, good tumor targeting, multiple tumor-killing pathways, and fewer adverse reactions. In recent years, oncolytic virus therapy has become a new hot topic in the field of tumor treatment research. The development of oncolytic viruses in China has progressed rapidly, with several companies' oncolytic virus drugs currently in clinical trials.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') officially released the 'Blue Book on the Development of China's Oncolytic Virus Industry' (hereinafter referred to as the 'Blue Book') on July 28, 2023. The aim is to conduct an in-depth analysis of the current development status, competitive landscape, capital interest, R&D barriers, etc., of the oncolytic virus industry, track the development context of the industry and technology, tap into the potential for industry development, analyze the driving factors behind market development, and hope to sort out the current industrial situation and reflect future growth trends for participants in the oncolytic virus industry.
